Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported second quarter 2026 financial results and provided corporate updates, highlighting positive tovecimig Phase 2/3 data and expected FDA feedback this quarter. The company is advancing clinical trials for several bispecific antibody candidates targeting cancers, including expansions for CTX-8371 and initiation of CTX-471 …